drugset / Trial / NCT01030679
Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the safety and effectiveness of three doses of CKD-501 compared to placebo in lowering fasting plasma glucose levels in people with type 2 diabetes for 8 weeks.
Timeline
- Start
- 2007-07
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lobeglitazone | Small molecule | 0.5 mg | Oral |
| Subject | Lobeglitazone | Small molecule | 1 mg | Oral |
| Subject | Lobeglitazone | Small molecule | 2 mg | Oral |